{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-009600","form_type":"8-K","ticker":"DARE","cik":"0001401914","company_name":"Dare Bioscience, Inc.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.765047+00:00","generated_at":"2026-06-17T09:06:07.076347+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dare Bioscience reports FY2022 cash $34.7M; XACIATO first commercial sale expected Q2 2023","bullets":["Cash and cash equivalents $34.7M at Dec 31, 2022, down from $51.7M at Dec 31, 2021.","G&A expenses $11.2M (FY2022) vs $8.4M (FY2021); R&D expenses $30.0M vs $30.6M.","Received $24.1M in non-dilutive funding in 2022: $10M from Organon license, $13.3M grants, $0.8M Australian rebate.","XACIATO first commercial sale expected Q2 2023, triggering $2.5M milestone to Dare.","Sildenafil Cream Phase 2b topline data targeted for Q2 2023; Ovaprene pivotal study initiation mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-009600","json":"https://secwatch.observer/filing/0001493152-23-009600.json","markdown":"https://secwatch.observer/filing/0001493152-23-009600.md","text":"https://secwatch.observer/filing/0001493152-23-009600.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401914/000149315223009600/0001493152-23-009600-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401914/000149315223009600/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:06:07.076347+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"84784277464ea18a65f6f754e89f8d531e73ac72","claim":"Dare Bioscience, Inc. reported financial results for the quarter and fiscal-year ended December 31, 2022.","evidence_excerpt":"On March 30, 2023, Daré Bioscience, Inc. issued a press release announcing its financial results for the quarter and fiscal-year ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401914/000149315223009600/0001493152-23-009600-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and fiscal-year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}